Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2012 (2012), Article ID 679013, 6 pages
http://dx.doi.org/10.1155/2012/679013
Review Article

Drug-Eluting Stents in Multivessel Coronary Artery Disease: Cost Effectiveness and Clinical Outcomes

1Department of Pharmacology, Nirma University, Ahmedabad, Gujarat 382 481, India
2Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad, Gujarat 380009, India

Received 2 July 2012; Revised 7 November 2012; Accepted 25 November 2012

Academic Editor: Alex Chen

Copyright © 2012 Kanaiya Panchal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics-2012 update: a report from the American heart association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012. View at Publisher · View at Google Scholar
  2. G. N. Levine, E. R. Bates, J. C. Blankenship et al., “2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, vol. 124, no. 23, pp. e574–e651, 2011. View at Publisher · View at Google Scholar
  3. A. Moustapha and H. V. Anderson, “Revascularization interventions for ischemic heart disease,” Current Opinion in Cardiology, vol. 15, no. 6, pp. 463–471, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. R. H. Stables, “Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial,” The Lancet, vol. 360, no. 9338, pp. 965–970, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Rodriguez, V. Bernardi, J. Navia et al., “Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results,” Journal of the American College of Cardiology, vol. 37, no. 1, pp. 51–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Schofer, M. Schlüter, A. H. Gershlick et al., “Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS),” The Lancet, vol. 362, no. 9390, pp. 1093–1099, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kastrati, J. Mehilli, J. Pache et al., “Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents,” The New England Journal of Medicine, vol. 356, no. 10, pp. 1030–1039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Versaci, A. Gaspardone, F. Tomai, F. Crea, L. Chiariello, and P. A. Gioffrè, “A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery,” The New England Journal of Medicine, vol. 336, no. 12, pp. 817–822, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. P. W. Serruys, M. J. B. Kutryk, and A. T. L. Ong, “Coronary-artery stents,” The New England Journal of Medicine, vol. 354, no. 5, pp. 483–495, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. R. L. Frye, E. L. Alderman, K. Andrews et al., “Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) investigators,” The New England Journal of Medicine, vol. 335, no. 4, pp. 217–225, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. A. E. Rodriguez, J. Baldi, C. F. Pereira et al., “Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II),” Journal of the American College of Cardiology, vol. 46, no. 4, pp. 582–588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. W. Serruys, A. T. L. Ong, L. A. Van Herwerden et al., “Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the arterial revascularization therapies study (ARTS) randomized trial,” Journal of the American College of Cardiology, vol. 46, no. 4, pp. 575–581, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Booth, T. Clayton, J. Pepper et al., “Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS),” Circulation, vol. 118, no. 4, pp. 381–388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Daemen, E. Boersma, M. Flather et al., “Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials,” Circulation, vol. 118, no. 11, pp. 1146–1154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Hlatky, D. B. Boothroyd, D. M. Bravata et al., “Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials,” The Lancet, vol. 373, no. 9670, pp. 1190–1197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. T. Stroupe, D. A. Morrison, M. A. Hlatky et al., “Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients,” Circulation, vol. 114, no. 12, pp. 1251–1257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. J. Cohen, B. Dulisse, J. Zhang et al., “Cost-effectiveness of PCI with or without drug-eluting stents vs bypass surgery for treatment of multivessel coronary disease: 1-year results from the ARTS I and ARTS II trials,” Circulation, vol. 112, supplement 2, article II-550, 2005, Abstract no. 2611. View at Google Scholar
  18. V. M. G. Legrand, P. W. Serruys, F. Unger et al., “Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease,” Circulation, vol. 109, no. 9, pp. 1114–1120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. B. Berger, M. H. Sketch Jr., and R. M. Califf, “Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)?” Circulation, vol. 109, no. 9, pp. 1079–1081, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Stettler, S. Wandel, S. Allemann et al., “Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis,” The Lancet, vol. 370, no. 9591, pp. 937–948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Spaulding, J. Daemen, E. Boersma, D. E. Cutlip, and P. W. Serruys, “A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents,” The New England Journal of Medicine, vol. 356, no. 10, pp. 989–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. W. Stone, J. W. Moses, S. G. Ellis et al., “Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents,” The New England Journal of Medicine, vol. 356, no. 10, pp. 998–1008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. E. L. Eisenstein, M. B. Leon, D. E. Kandzari et al., “Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the Cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial,” JACC, vol. 2, no. 12, pp. 1199–1207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. W. Serruys, P. Ruygrok, J. Neuzner et al., “A randomised comparison of an everolimus-eluting coronary stent with a Paclitaxel eluting coronary stent: the SPIRIT II trial,” EuroIntervention, vol. 2, pp. 286–294, 2006. View at Google Scholar
  25. A. Jeremias and A. Kirtane, “Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention,” Annals of Internal Medicine, vol. 148, no. 3, pp. 234–238, 2008. View at Google Scholar · View at Scopus
  26. A. A. Bavry, D. J. Kumbhani, T. J. Helton, P. P. Borek, G. R. Mood, and D. L. Bhatt, “Late thrombosis of drug-eluting stents: a metaanalysis of randomized clinical trials,” American Journal of Medicine, vol. 119, no. 12, pp. 1056–1061, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Farb and A. B. Boam, “Stent thrombosis redux—the FDA perspective,” The New England Journal of Medicine, vol. 356, no. 10, pp. 984–987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. D. T. Ko, M. Chiu, H. Guo et al., “Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications,” Journal of the American College of Cardiology, vol. 53, no. 19, pp. 1773–1782, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Kirtane, A. Gupta, S. Iyengar et al., “Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies,” Circulation, vol. 119, no. 25, pp. 3198–3206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. A. Bittl, “Editorial: bioresorbable stents: the next revolution,” Circulation, vol. 122, no. 22, pp. 2236–2238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. P. W. Serruys, Y. Onuma, J. A. Ormiston et al., “Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes,” Circulation, vol. 122, no. 22, pp. 2301–2312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. P. W. Serruys, Y. Onuma, D. Dudek et al., “Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de Novo Coronary Artery stenosis: 12-month clinical and imaging outcomes,” Journal of the American College of Cardiology, vol. 58, no. 15, pp. 1578–1588, 2011. View at Publisher · View at Google Scholar
  33. D. Dudek, Y. Onuma, J. A. Ormiston, L. Thuesen, K. Miquel-Hebert, and P. W. Serruys, “Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial,” EuroIntervention, vol. 7, no. 9, pp. 1060–1061, 2012. View at Publisher · View at Google Scholar
  34. P. W. Serruys, Y. Onuma, S. Garg et al., “5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions,” Journal of the American College of Cardiology, vol. 55, no. 11, pp. 1093–1101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. E. Rodriguez, A. O. Maree, J. Mieres et al., “Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 Years follow-up of the ERACI III registry,” European Heart Journal, vol. 28, no. 17, pp. 2118–2125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. U. Benedetto, G. Melina, E. Angeloni et al., “Coronary artery bypass grafting versus drug-eluting stents in multivessel coronary disease. A meta-analysis on 24,268 patients,” European Journal of Cardio-thoracic Surgery, vol. 36, no. 4, pp. 611–615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. D. W. Park, Y. H. Kim, H. G. Song et al., “Long-term comparison of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization: 5-year outcomes from the asan medical center-multivessel revascularization registry,” Journal of the American College of Cardiology, vol. 57, no. 2, pp. 128–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. P. W. Serruvs, M. C. Morice, A. P. Kappetein et al., “Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease,” The New England Journal of Medicine, vol. 360, no. 10, pp. 961–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. P. Kappetein, T. E. Feldman, M. J. MacK et al., “Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial,” European Heart Journal, vol. 32, no. 17, pp. 2125–2134, 2011. View at Publisher · View at Google Scholar
  40. “Four years follow up of the SYNTAX trial: optimal revascularization strategy in patients with three vessel disease and/or left main disease,” Journal of the American College of Cardiology, vol. 58, article 61, 2011.
  41. A. Kapur, R. J. Hall, I. S. Malik et al., “Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial,” Journal of the American College of Cardiology, vol. 55, no. 5, pp. 432–440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. P. Banning, S. Westaby, M. C. Morice et al., “Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents,” Journal of the American College of Cardiology, vol. 55, no. 11, pp. 1067–1075, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Onuma, J. J. Wykrzykowska, S. Garg, P. Vranckx, and P. W. Serruys, “5-year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (Arterial revascularization therapy study)-II and ARTS-I trials,” JACC, vol. 4, no. 3, pp. 317–323, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. S. Lee, T. Yang, J. Dhoot, Z. Iqbal, and H. Liao, “Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease,” American Journal of Cardiology, vol. 105, no. 11, pp. 1540–1544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. E. Farkouh, G. Dangas, M. B. Leon et al., “Design of the future revascularization evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM) trial,” American Heart Journal, vol. 155, no. 2, pp. 215–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M. E. Farkouh, M. Domanski, L. A. Sleep et al., “Strategies for multivessel revascularization in patients with diabetes,” The New England Journal of Medicine. In press. View at Publisher · View at Google Scholar
  47. D. J. Cohen, A. Bakhai, C. Shi et al., “Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial,” Circulation, vol. 110, no. 5, pp. 508–514, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Kaiser, H. P. Brunner-La Rocca, P. T. Buser et al., “Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET),” The Lancet, vol. 366, no. 9489, pp. 921–929, 2005. View at Publisher · View at Google Scholar
  49. S. Rinfret, D. J. Cohen, A. A. Tahami Monfared, J. LeLorier, J. Mireault, and E. Schampaert, “Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial,” American Journal of Cardiovascular Drugs, vol. 6, no. 3, pp. 159–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Bakhai, G. W. Stone, E. Mahoney et al., “Cost effectiveness of Paclitaxel eluting stents for patients undergoing percutaneous coronary revascularization. Results from the TAXUS-IV trial,” Journal of the American College of Cardiology, vol. 48, no. 2, pp. 253–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. D. G. Sionis and I. T. Iakovou, “Cost-effectiveness of drug-eluting stents,” Hellenic Journal of Cardiology, vol. 47, no. 5, pp. 292–297, 2006. View at Google Scholar · View at Scopus
  52. D. J. Cohen, T. A. Lavelle, B. Van Hout et al., “Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial,” Catheterization and Cardiovascular Interventions, vol. 79, no. 2, pp. 198–209, 2012. View at Publisher · View at Google Scholar
  53. D. J. Cohen, B. Van Hout, P. W. Serruys et al., “Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery,” The New England Journal of Medicine, vol. 364, no. 11, pp. 1016–1026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Perikhanyan, “Effectiveness and cost-effectiveness of coronary artery bypass surgery versus drug eluting stents in Armenia: a feasibility study,” Georgian Medical News, no. 195, pp. 44–51, 2011. View at Google Scholar
  55. M. Gyoengyoesi, L. Krenn, D. Glogarand et al., “Cost-effectiveness of percutaneous coronary intervention with taxus stents in patients with multivessel coronary artery disease compared with aortocoronary bypass surgery 5 years after intervention,” Journal of the American College of Cardiology, vol. 59, no. 13, supplement, Article ID E1442, 2012. View at Google Scholar
  56. E. A. Magnuson, Late-Breaking Clinical Trials: Health Economics and Quality of Life in Contemporary Trials, American Heart Association Scientific Sessions, Los Angeles, NY, USA, 2012.